Historical Valuation
IDEXX Laboratories Inc (IDXX) is now in the Fair zone, suggesting that its current forward PE ratio of 47.56 is considered Fairly compared with the five-year average of 50.33. The fair price of IDEXX Laboratories Inc (IDXX) is between 546.45 to 838.11 according to relative valuation methord.
Relative Value
Fair Zone
546.45-838.11
Current Price：713.35
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
IDEXX Laboratories Inc (IDXX) has a current Price-to-Book (P/B) ratio of 34.33. Compared to its 3-year average P/B ratio of 33.26 , the current P/B ratio is approximately 3.23% higher. Relative to its 5-year average P/B ratio of 46.86, the current P/B ratio is about -26.74% higher. IDEXX Laboratories Inc (IDXX) has a Forward Free Cash Flow (FCF) yield of approximately 1.80%. Compared to its 3-year average FCF yield of 1.77%, the current FCF yield is approximately 1.70% lower. Relative to its 5-year average FCF yield of 1.62% , the current FCF yield is about 11.03% lower.
P/B
Median3y
33.26
Median5y
46.86
FCF Yield
Median3y
1.77
Median5y
1.62
Competitors Valuation Multiple
AI Analysis for IDXX
The average P/S ratio for IDXX competitors is 5.87, providing a benchmark for relative valuation. IDEXX Laboratories Inc Corp (IDXX.O) exhibits a P/S ratio of 11.74, which is 99.97% above the industry average. Given its robust revenue growth of 13.29%, this premium appears unsustainable.
Performance Decomposition
AI Analysis for IDXX
1Y
3Y
5Y
Market capitalization of IDXX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of IDXX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is IDXX currently overvalued or undervalued?
IDEXX Laboratories Inc (IDXX) is now in the Fair zone, suggesting that its current forward PE ratio of 47.56 is considered Fairly compared with the five-year average of 50.33. The fair price of IDEXX Laboratories Inc (IDXX) is between 546.45 to 838.11 according to relative valuation methord.
What is IDEXX Laboratories Inc (IDXX) fair value?
IDXX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of IDEXX Laboratories Inc (IDXX) is between 546.45 to 838.11 according to relative valuation methord.
How does IDXX's valuation metrics compare to the industry average?
The average P/S ratio for IDXX's competitors is 5.87, providing a benchmark for relative valuation. IDEXX Laboratories Inc Corp (IDXX) exhibits a P/S ratio of 11.74, which is 99.97% above the industry average. Given its robust revenue growth of 13.29%, this premium appears unsustainable.
What is the current P/B ratio for IDEXX Laboratories Inc (IDXX) as of Jan 10 2026?
As of Jan 10 2026, IDEXX Laboratories Inc (IDXX) has a P/B ratio of 34.33. This indicates that the market values IDXX at 34.33 times its book value.
What is the current FCF Yield for IDEXX Laboratories Inc (IDXX) as of Jan 10 2026?
As of Jan 10 2026, IDEXX Laboratories Inc (IDXX) has a FCF Yield of 1.80%. This means that for every dollar of IDEXX Laboratories Inc’s market capitalization, the company generates 1.80 cents in free cash flow.
What is the current Forward P/E ratio for IDEXX Laboratories Inc (IDXX) as of Jan 10 2026?
As of Jan 10 2026, IDEXX Laboratories Inc (IDXX) has a Forward P/E ratio of 47.56. This means the market is willing to pay $47.56 for every dollar of IDEXX Laboratories Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for IDEXX Laboratories Inc (IDXX) as of Jan 10 2026?
As of Jan 10 2026, IDEXX Laboratories Inc (IDXX) has a Forward P/S ratio of 11.74. This means the market is valuing IDXX at $11.74 for every dollar of expected revenue over the next 12 months.